Redirecting adult mesenchymal stromal cells to the brain

a new approach for treating CNS autoimmunity and neuroinflammation?

Jasmine J. Wilson, Kerrie L. Foyle, Jade Foeng, Todd Norton, Duncan R. McKenzie, Natalie Payne, Claude C. Bernard, Shaun R. McColl, Iain Comerford

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

Mesenchymal stromal cells or stem cells (MSCs) have been shown to participate in tissue repair and are immunomodulatory in neuropathological settings. Given this, their potential use in developing a new generation of personalized therapies for autoimmune and inflammatory diseases of the central nervous system (CNS) will be explored. To effectively exert these effector functions, MSCs must first gain entry into damaged neural tissues, a process that has been demonstrated to be a limiting factor in their therapeutic efficacy. In this review, we discuss approaches to maximize the therapeutic efficacy of MSCs by altering their intrinsic trafficking programs to effectively enter neuropathological sites. To this end, we explore the significant role of chemokine receptors and adhesion molecules in directing cellular traffic to the inflamed CNS and the capacity of MSCs to adopt these molecular mechanisms to gain entry to this site. We postulate that understanding and exploiting these migratory mechanisms may be key to the development of cell-based therapies tailored to respond to the migratory cues unique to the nature and stage of progression of individual CNS disorders.

Original languageEnglish
Pages (from-to)347-357
Number of pages11
JournalImmunology and Cell Biology
Volume96
Issue number4
DOIs
Publication statusPublished - 1 Apr 2018

Keywords

  • Cell migration
  • central nervous system
  • chemokine receptor
  • mesenchymal stem cell
  • mesenchymal stromal cell
  • neuroinflammation

Cite this

Wilson, Jasmine J. ; Foyle, Kerrie L. ; Foeng, Jade ; Norton, Todd ; McKenzie, Duncan R. ; Payne, Natalie ; Bernard, Claude C. ; McColl, Shaun R. ; Comerford, Iain. / Redirecting adult mesenchymal stromal cells to the brain : a new approach for treating CNS autoimmunity and neuroinflammation?. In: Immunology and Cell Biology. 2018 ; Vol. 96, No. 4. pp. 347-357.
@article{13a553ee31ae42039e27e21730aadb9a,
title = "Redirecting adult mesenchymal stromal cells to the brain: a new approach for treating CNS autoimmunity and neuroinflammation?",
abstract = "Mesenchymal stromal cells or stem cells (MSCs) have been shown to participate in tissue repair and are immunomodulatory in neuropathological settings. Given this, their potential use in developing a new generation of personalized therapies for autoimmune and inflammatory diseases of the central nervous system (CNS) will be explored. To effectively exert these effector functions, MSCs must first gain entry into damaged neural tissues, a process that has been demonstrated to be a limiting factor in their therapeutic efficacy. In this review, we discuss approaches to maximize the therapeutic efficacy of MSCs by altering their intrinsic trafficking programs to effectively enter neuropathological sites. To this end, we explore the significant role of chemokine receptors and adhesion molecules in directing cellular traffic to the inflamed CNS and the capacity of MSCs to adopt these molecular mechanisms to gain entry to this site. We postulate that understanding and exploiting these migratory mechanisms may be key to the development of cell-based therapies tailored to respond to the migratory cues unique to the nature and stage of progression of individual CNS disorders.",
keywords = "Cell migration, central nervous system, chemokine receptor, mesenchymal stem cell, mesenchymal stromal cell, neuroinflammation",
author = "Wilson, {Jasmine J.} and Foyle, {Kerrie L.} and Jade Foeng and Todd Norton and McKenzie, {Duncan R.} and Natalie Payne and Bernard, {Claude C.} and McColl, {Shaun R.} and Iain Comerford",
year = "2018",
month = "4",
day = "1",
doi = "10.1111/imcb.12014",
language = "English",
volume = "96",
pages = "347--357",
journal = "Immunology and Cell Biology",
issn = "0818-9641",
publisher = "John Wiley & Sons",
number = "4",

}

Redirecting adult mesenchymal stromal cells to the brain : a new approach for treating CNS autoimmunity and neuroinflammation? / Wilson, Jasmine J.; Foyle, Kerrie L.; Foeng, Jade; Norton, Todd; McKenzie, Duncan R.; Payne, Natalie; Bernard, Claude C.; McColl, Shaun R.; Comerford, Iain.

In: Immunology and Cell Biology, Vol. 96, No. 4, 01.04.2018, p. 347-357.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Redirecting adult mesenchymal stromal cells to the brain

T2 - a new approach for treating CNS autoimmunity and neuroinflammation?

AU - Wilson, Jasmine J.

AU - Foyle, Kerrie L.

AU - Foeng, Jade

AU - Norton, Todd

AU - McKenzie, Duncan R.

AU - Payne, Natalie

AU - Bernard, Claude C.

AU - McColl, Shaun R.

AU - Comerford, Iain

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Mesenchymal stromal cells or stem cells (MSCs) have been shown to participate in tissue repair and are immunomodulatory in neuropathological settings. Given this, their potential use in developing a new generation of personalized therapies for autoimmune and inflammatory diseases of the central nervous system (CNS) will be explored. To effectively exert these effector functions, MSCs must first gain entry into damaged neural tissues, a process that has been demonstrated to be a limiting factor in their therapeutic efficacy. In this review, we discuss approaches to maximize the therapeutic efficacy of MSCs by altering their intrinsic trafficking programs to effectively enter neuropathological sites. To this end, we explore the significant role of chemokine receptors and adhesion molecules in directing cellular traffic to the inflamed CNS and the capacity of MSCs to adopt these molecular mechanisms to gain entry to this site. We postulate that understanding and exploiting these migratory mechanisms may be key to the development of cell-based therapies tailored to respond to the migratory cues unique to the nature and stage of progression of individual CNS disorders.

AB - Mesenchymal stromal cells or stem cells (MSCs) have been shown to participate in tissue repair and are immunomodulatory in neuropathological settings. Given this, their potential use in developing a new generation of personalized therapies for autoimmune and inflammatory diseases of the central nervous system (CNS) will be explored. To effectively exert these effector functions, MSCs must first gain entry into damaged neural tissues, a process that has been demonstrated to be a limiting factor in their therapeutic efficacy. In this review, we discuss approaches to maximize the therapeutic efficacy of MSCs by altering their intrinsic trafficking programs to effectively enter neuropathological sites. To this end, we explore the significant role of chemokine receptors and adhesion molecules in directing cellular traffic to the inflamed CNS and the capacity of MSCs to adopt these molecular mechanisms to gain entry to this site. We postulate that understanding and exploiting these migratory mechanisms may be key to the development of cell-based therapies tailored to respond to the migratory cues unique to the nature and stage of progression of individual CNS disorders.

KW - Cell migration

KW - central nervous system

KW - chemokine receptor

KW - mesenchymal stem cell

KW - mesenchymal stromal cell

KW - neuroinflammation

UR - http://www.scopus.com/inward/record.url?scp=85042653856&partnerID=8YFLogxK

U2 - 10.1111/imcb.12014

DO - 10.1111/imcb.12014

M3 - Review Article

VL - 96

SP - 347

EP - 357

JO - Immunology and Cell Biology

JF - Immunology and Cell Biology

SN - 0818-9641

IS - 4

ER -